Jankey M 1000 Tablet SR is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 1000 mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the levels of incretin hormones, which increase insulin synthesis and release from pancreatic beta cells and decrease glucagon secretion from alpha cells, thereby reducing hepatic glucose production. Metformin, a biguanide, primarily acts by decreasing hepatic gluconeogenesis and improving peripheral insulin sensitivity, leading to enhanced glucose uptake and utilization. The sustained-release (SR) formulation of Metformin in Jankey M 1000 ensures a gradual release of the drug, minimizing gastrointestinal side effects commonly associated with immediate-release formulations and improving patient compliance. This combination therapy is indicated for adults with type 2 diabetes inadequately controlled by diet and exercise alone or when monotherapy with either agent does not provide adequate glycemic control. Jankey M 1000 should be used as part of a comprehensive diabetes management plan that includes diet, exercise, and regular monitoring of blood glucose levels. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular follow-up is essential to assess efficacy and safety.